NCT05769725招募中2 期
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer(PD-L1 + / MSI-H / EBV +/dMMR)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- DFS
研究概览
简要总结
To evaluate the efficacy and safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR) . Secondary study objective: To observe and evaluate the overall survival and adverse events of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1+ / MSI-H / EBV +/dMMR). To evaluate the safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). To explore the incidence of PD-L1 + / MSI-H / EBV + /dMMR in stage IIIc gastric cancer. To explore the correlation of PD-L1 + / MSI-H / EBV + /dMMR in stage IIIc gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients voluntarily joined the study and signed the informed consent; ≥ 18 years old, ≤ 75 years old, both male and female; Stage III gastric cancer confirmed by pathology, ECoG score: 0-1 Detection of biomarkers in postoperative gastric cancer samples suggests that: PD-L1 + CPS ≥ 5 / MSI-H + / EBV+/dMMR No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and local treatment During the study treatment period and within 3 months after the end of the study treatment period, a medically recognized contraceptive measure (such as IUD, contraceptive pill or condom) should be used for the female patients of non-surgical sterilization or childbearing age; the serum or urine HCG test of the female patients of non-surgical sterilization must be negative within 72 hours before the study group; and the hCG test must be non lactation; for the male patients Sex, should be surgical sterilization, or agree to use appropriate methods of contraception during the trial and within 3 months after the last administration of the test drug.
- •The baseline blood routine and biochemical indexes of the selected patients should meet the following standards:
- •A. hemoglobin ≥ 90g / L
- •B. absolute neutrophil count ≥ 1.5 × 10 ^ 9 / L
- •C. platelet count ≥ 100 × 10 ^ 9 / L
- •D. ASTor ALT ≤ 2.5 ULN
- •E. Alkaline phosphatase (ALP)≤ 2.5×ULN
- •TSH ≤ 1 ULN (if abnormal, T3 and T4 levels should be examined at the same time, if T3 and T4 levels are normal, they can be included in the group);
排除标准
- •Pregnant or lactating women; Women of childbearing age were positive in the baseline pregnancy test; Distant metastasis was diagnosed by CT /MR/ EUS. Received previous anti-tumor treatment, including chemotherapy, radiotherapy or immunotherapy; Have other malignant tumors in the past 5 years (except basal cell or squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ or breast cancer); Uncontrollable pleural effusion, pericardial effusion or ascites; Severe cardiovascular diseases such as symptomatic coronary heart disease, congestive heart failure ≥ level II, uncontrolled arrhythmia and myocardial infarction within 12 months before admission; With gastroduodenal obstruction/bleeding, digestive dysfunction or malabsorption syndrome Complicated with severe uncontrolled concurrent infection or other serious uncontrolled concomitant diseases, moderate or severe renal injury; Allergic reaction to the drugs used in this study; Steroid or other systemic immunosuppressive therapy was used 14 days before admission; Patients who received study drug treatment within 4 weeks before enrollment (participate in other clinical trials).
- •Active autoimmune diseases (including but not limited to: uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchodilator treatment). Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected.
- •History of primary immunodeficiency. Immunosuppressive drugs were used within 4 weeks prior to the first dose of study treatment, excluding local or physiological doses of systemic glucocorticoids (i.e. no more than 10mg / day of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents.
- •Receive live attenuated vaccine within 4 weeks before the first dose of study treatment or during the study period.
- •Active tuberculosis is known. We have known the history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥ 10 ⁴ copies / ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time);.
- •Other factors that may affect the safety or test compliance of the subjects according to the judgment of the researchers. For example, serious diseases (including mental diseases) requiring combined treatment, serious laboratory abnormalities, or other family or social factors, etc.
研究组 & 干预措施
Serplulimab in Combination With Docetaxel +S-1
Experimental
干预措施: S1 (Drug)
Serplulimab in Combination With Docetaxel +S-1
Experimental
干预措施: Serplulimab (Drug)
Serplulimab in Combination With Docetaxel +S-1
Experimental
干预措施: Docetaxel (Drug)
Docetaxel +S-1
Placebo Comparator
干预措施: Docetaxel (Drug)
Docetaxel +S-1
Placebo Comparator
干预措施: S1 (Drug)
结局指标
主要结局
DFS
时间窗: 1 years
disease-free survival
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric CancerGastric Cancer Stage IIINCT04152889RenJi Hospital20
进行中（未招募）
3 期
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVNCT01933932AstraZeneca510
暂停
1 期
Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.Gastric CancerNCT00209729Hokkaido Gastrointestinal Cancer Study Group50
已完成
2 期
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerMetastatic gastric cancer (Advanced or recurrent gastric cancer)JPRN-C000000103Hiroshima Cancer Therapy Development Organization (HiCTDO)50
已完成
1 期
Phase I/II Study of Docetaxel and S-1 Combination Therapy for Advanced Non-small Cell Lung CancerJPRN-C000000281The Tokyo Cooperative Oncology Group60